**Core tip:** Diabetes mellitus is potentially reversible especially with bariatric surgery. Intensive medical management is promising but the evidence is weaker. The subgroup that is likely to go into prolonged remission is those with insulin resistance, short duration of diabetes and obesity. Further research is needed to identify those that can go into remission and how to use intensive medical management to achieve this.

INTRODUCTION
============

The number of adults with diabetes in the world has increased from 108 million in 1980 to 422 million in 2014 due to rise in prevalence, population growth and ageing\[[@B1]\]. Diabetes Mellitus has been projected to become the 7^th^ leading causes of death in 2030\[[@B2]\]. It has been estimated that the direct medical costs of diabetes to the world is more than United States \$827 million\[[@B2]\]. It is well-established that prediabetes is reversible\[[@B3]-[@B7]\], but it is unclear whether diabetes is reversible once it has been diagnosed.

Type 2 diabetes mellitus is potentially reversible\[[@B8]\]. A better term to use would be remission which is defined to be achieving glucose level below the diabetic range in the absence of active pharmacologic or surgical therapy\[[@B9]\]. It can further be divided into partial or complete and if complete remission lasts for more than 5 years, it would be considered as prolonged remission\[[@B9]\]. In community settings, in the absence of bariatric surgery, the 7-year cumulative incidence of partial, complete or prolonged remission was found to be 1.47% (1.40%-1.54%), 0.14% (0.12%-0.16%) and 0.007% (0.003%-0.020%)\[[@B10]\] which is very low.

In this narrative review, the evidence of reversibility of diabetes mellitus will be reviewed in light of new studies recently published. This can help stimulate interest in prolonged remission as a treatment target for patients with established diabetes.

BARIATRIC SURGERY
=================

There are several systematic reviews on the impact of bariatric surgery on diabetes mellitus\[[@B11]-[@B13]\] and some have distinguished between type 1 diabetes\[[@B14]-[@B16]\] and type 2 diabetes\[[@B17]-[@B20]\] (Table [1](#T1){ref-type="table"}). The percentage of diabetes remission after bariatric surgery is estimated to be 76.8%\[[@B12]\] to 92%\[[@B11]\]. However, the exact physiological and molecular mechanisms behind diabetes remission after bariatric surgery remains incompletely understood\[[@B21],[@B22]\]. (Figure [1](#F1){ref-type="fig"}) There are several reviews that looked at the role of bariatric surgery in managing diabetes mellitus\[[@B23]-[@B26]\] and the mechanism behind reversibility of type 2 diabetes mellitus\[[@B27],[@B28]\] All agree that diabetes remission can be an important outcome to look at after bariatric surgery and there are many risk prediction models which can predict diabetes remission\[[@B29]\].

###### 

Bariatric surgery systematic reviews

  **Ref**.                          **Type of diabetes**       **No. of studies included**                                         **Remission percentage (95%CI)**
  --------------------------------- -------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Chang et al\[[@B11]\], 2014       Not specified              164 (37 randomized clinical trials and 127 observational studies)   Randomized clinical trials: 92% (85%-97%) Observational studies: 86% (79%-92%)
  Buchwald et al\[[@B12]\], 2004    Not specified              136                                                                 76.8% (70.7%-82.9%)
  Gloy et al\[[@B13]\], 2013        Not specified              11                                                                  59.90%
  Ashrafian et al\[[@B14]\], 2015   Type 1 diabetes mellitus   27                                                                  Weighted mean decrease in insulin requirement: 44.5 units 78.1% (73.8%-82.3%)
  Chow et al\[[@B15]\], 2016        Type 1 diabetes mellitus   13                                                                  Weighted mean total daily insulin requirement decreased from 98 +/- 26 IU/d to 42 +/- 11 IU/d
  Mahawar et al\[[@B16]\], 2016     Type 1 diabetes mellitus   15                                                                  Not reported
  Buchwald et al\[[@B17]\], 2009    Type 2 diabetes mellitus   621                                                                 76.2% insulin free
  Baskota et al\[[@B18]\], 2015     Type 2 diabetes mellitus   10                                                                  61.8% medication free
  Goh et al\[[@B19]\], 2017         Type 2 diabetes mellitus   24                                                                  Remission rate Duodenal-jejunal bypass: 20%-40% Duodenal-jejunal bypass with sleeve gastrectomy: 79%-93% Duodenal-jejunal bypass sleeve: 62.5%-100% Ileal interposition with sleeve gastrectomy: 47%-95.7%
  Yan et al\[[@B20]\]               Type 2 diabetes mellitus   6                                                                   Type 2 diabetes mellitus remission rate for roux-en-y gastric bypass *vs* medical treatment: OR: 76.4 (95%CI: 20.7-281.7)

![Potential mechanisms contributing to improved glycaemia after roux-en-Y gastric bypass and vertical sleeve gastrectomy. A: Immediate effects of improved glycaemia after roux-en-Y gastric bypass and vertical sleeve gastrectomy due to anatomical changes; B: Potential mediators/mechanisms involved. Cross talk occurs among these factors; C: Effects on glucose homeostasis\[[@B21]\]; RYGB: Roux-en-Y gastric bypass; SG: Sleeve gastrectomy.](WJD-9-127-g001){#F1}

Besides diabetes remission, bariatric surgery may also reduce inflammation\[[@B30],[@B31]\], improve renal function\[[@B31]\], reduce cardiovascular risk\[[@B32]\] and reduce microvascular and macrovascular complications\[[@B33]\]. The impact of bariatric surgery on all these remains incompletely understood.

Even if the evidence is strong for remission of diabetes after bariatric surgery, it is unlikely to be advocated at the population level due to the high cost and lack of surgeons well trained to perform bariatric surgeries. Furthermore, the indication for bariatric surgery is currently for patients with a body mass index above 35 kg/m^2^ or between 30 and 35 kg/m^2^ with inadequate glycemic control despite optimal medical treatment\[[@B34]\]. This would not benefit diabetes patients who are non-obese (body mass index \< 30 kg/m^2^) and the remission rate has been shown to be much lower in non-obese diabetes patients\[[@B18]\].

PANCREAS TRANSPLANTATION AND ISLET CELL TRANSPLANTATION
=======================================================

A recent review found that there is a need for multicenter randomized trials in pancreas transplantation to define clearly the efficacy, risks, and long term benefits due to lack of high quality evidence\[[@B35]\]. The indications for pancreas transplantation alone are in patients with severe metabolic complications, incapacitating problems with exogenous insulin therapy and failure of insulin based management to prevent acute complication\[[@B35]\]. It would not be to induce diabetes into remission. A systematic review on islet cell transplantation for type 1 diabetes mellitus has also concluded that there is low to very low quality evidence for all outcomes of interest such as remission of diabetes\[[@B36]\].

The next question to ask is whether pancreas transplantation is able to reverse complications of diabetes such as diabetic nephropathy. A recent study has demonstrated that diabetic nephropathy may be reversible after pancreas transplantation\[[@B37]\] that is contrary to current thinking. Further research is needed to look at whether it is possible to reverse diabetes and/or its complications after pancreas or islet cell transplantation.

INTENSIVE MEDICAL MANAGEMENT
============================

There are relatively fewer studies on non-surgical remission of diabetes mellitus. A randomized controlled trial found that 40.7% of patients with type 2 diabetes for less than 3 years had complete or partial remission at 12 mo\[[@B38]\]. A cluster-randomized trial found that primary care-led weight management achieved a remission rate of 46% at 12 mo in patients with type 2 diabetes for less than 6 years\[[@B39]\]. A retrospective observational study of obese patients with type 2 diabetes found that 4.6 % achieved partial or complete diabetes remission after a 12-wk intensive program for diabetes weight management\[[@B40]\]. These studies did not look at the long term effectiveness of such intervention of the remission of type 2 diabetes mellitus and whether the same effect could be seen in patients with type 1 diabetes, non- obese diabetes patients or those with longer duration of type 2 diabetes.

Further research is needed to evaluate the long term effectiveness and safety of intensive medical management before recommending this but the results seem promising.

CLUSTERS OF DIABETES MELLITUS
=============================

A recent study has identified 5 replicable clusters of adult-onset diabetes with different disease progression and risk of diabetes complications\[[@B41]\]. The 5 clusters are

severe autoimmune diabetes (SAID), severe insulin-deficient diabetes (SIDD), severe insulin-resistant diabetes (SIRD), mild obesity-related diabetes (MOD) and mild age-related diabetes (MARD)\[[@B41]\](Table [2](#T2){ref-type="table"}).

###### 

Subgroups of adult-onset diabetes

  **Subgroups**                       **Body-mass index**   **Metabolic control**   **Insulin deficiency/resistance**
  ----------------------------------- --------------------- ----------------------- -----------------------------------
  Severe autoimmune diabetes          Relatively low        Poor                    Insulin deficiency
  Severe insulin-deficient diabetes   Relatively low        Poor                    Insulin deficiency
  Severe insulin-resistant diabetes   High                  Fair                    Insulin resistance
  Mild obesity-related diabetes       High                  Fair                    Insulin resistance
  Mild age-related diabetes           Relatively low        Fair                    Insulin resistance

Of the 5, it would be interesting to see which are more likely to go into prolonged remission with either bariatric surgery or intensive medical intervention so that clinicians can better define their treatment end-goals and treat accordingly. Based on insulin resistance, it would likely be SIRD, MOD and MARD that could go into prolonged remission.

Researchers may want to collect baseline data on glutamate decarboxylase antibodies, age at diagnosis, body mass index, glycated haemoglobin, and homeostatic model assessment 2 estimates of β-cell function and insulin resistance in future studies.

CONCLUSION
==========

Diabetes Mellitus especially type 2 diabetes can go into prolonged remission *via* bariatric surgery or intensive medical therapy. The current evidence for bariatric surgery is stronger than intensive medical management but intensive medical management is likely to have a greater impact in type 2 diabetes management. More research is needed to understand the mechanism behind prolonged remission and to identify the group of diabetes patients that will benefit the most from such interventions.
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